Literature DB >> 16055223

An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold.

Christal L Vitiello1, Carl R Merril, Sankar Adhya.   

Abstract

In experiments with germ free mice, free from adaptive antibodies to the bacterial virus lambda phage, titers of the virus in the circulatory system have been reported to decrease by more than 10(9)pfu within 48 h of intraperitoneal intravenous or oral administration. Based on these observations, serial passage techniques have been used to select lambda phage mutants, with 13,000-16,000-fold greater capacity to remain in the mouse circulatory system 24h after intraperitoneal injection. In these prior studies the "long-circulating" phage, designated lambdaArgo phage, had at least three mutations including one in the major phage capsid (E) protein, which resulted in the change of glutamic acid to a lysine at residue 158. In the current study, we demonstrate that this single specific substitution in the E protein is sufficient to confer the "long-circulating" phenotype. The isogenic pair of phage developed in this study consisting of the long-circulating marker-rescued lambdaArgo phage, and the parental wild type phage can be used for studies of viral recognition mechanisms of the innate immune system and for the development of more effective antibacterial therapeutic phage strains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16055223     DOI: 10.1016/j.virusres.2005.05.014

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  30 in total

1.  Epidermal growth factor targeting of bacteriophage to the choroid plexus for gene delivery to the central nervous system via cerebrospinal fluid.

Authors:  Ana Maria Gonzalez; Wendy Leadbeater; Sonia Podvin; Alexandra Borboa; Michael Burg; Ritsuko Sawada; James Rayner; Karen Sims; Tetsuya Terasaki; Conrad Johanson; Edward Stopa; Brian Eliceiri; Andrew Baird
Journal:  Brain Res       Date:  2010-08-21       Impact factor: 3.252

2.  Plasma clearance of bacteriophage Qbeta particles as a function of surface charge.

Authors:  Duane E Prasuhn; Pratik Singh; Erica Strable; Steven Brown; Marianne Manchester; M G Finn
Journal:  J Am Chem Soc       Date:  2008-01-05       Impact factor: 15.419

Review 3.  Design rules for nanomedical engineering: from physical virology to the applications of virus-based materials in medicine.

Authors:  Amy M Wen; Pooja H Rambhia; Roger H French; Nicole F Steinmetz
Journal:  J Biol Phys       Date:  2013-04-19       Impact factor: 1.365

Review 4.  Phage Therapy in the Era of Synthetic Biology.

Authors:  E Magda Barbu; Kyle C Cady; Bolyn Hubby
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

Review 5.  Design of virus-based nanomaterials for medicine, biotechnology, and energy.

Authors:  Amy M Wen; Nicole F Steinmetz
Journal:  Chem Soc Rev       Date:  2016-07-25       Impact factor: 54.564

Review 6.  Biofilm control with natural and genetically-modified phages.

Authors:  Amir Mohaghegh Motlagh; Ananda Shankar Bhattacharjee; Ramesh Goel
Journal:  World J Microbiol Biotechnol       Date:  2016-03-01       Impact factor: 3.312

Review 7.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

8.  Pseudovirions as vehicles for the delivery of siRNA.

Authors:  Paul E Lund; Ryan C Hunt; Michael M Gottesman; Chava Kimchi-Sarfaty
Journal:  Pharm Res       Date:  2009-12-09       Impact factor: 4.200

9.  A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.

Authors:  J J Bull; E R Vimr; I J Molineux
Journal:  Virology       Date:  2009-12-16       Impact factor: 3.616

10.  Phage Therapy - Everything Old is New Again.

Authors:  Andrew M Kropinski
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.